[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pharmacology](https://durgical.com/en/pharmacology/) › [Antineoplastic monoclonal antibodies](https://durgical.com/en/pharmacology/classes/antineoplastic-monoclonal-antibodies/) › Amivantamab # Amivantamab ## Antineoplastic monoclonal antibodies? Antineoplastic monoclonal antibodies ## High alert? An error with this medicine can cause serious harm: double checks and protocols are used. ## Pregnancy: avoid? Avoid in pregnancy. It may harm the fetus: a pregnancy test is done first, contraception is used during and for months after treatment, and breastfeeding is stopped. A bispecific antibody that hits both EGFR and MET; used in EGFR-mutated lung cancer. Infusion reactions and skin rash are common. Updated Nov 12, 2026 Also called: amivantamab-vmjw ## Quick facts **Group** [Antineoplastic monoclonal antibodies](https://durgical.com/en/pharmacology/classes/antineoplastic-monoclonal-antibodies/) **Target** EGFR and MET receptors (bispecific antibody) **Key effects** Acne-like rash · Nail fold inflammation · Nausea **Monitor** Vital signs and symptoms during · Eye symptoms **ATC** L01FX18 No doses: the clinician sets them by the current guideline. On this page - The basics Mechanism of action - Indications - Adverse effects - Pharmacokinetics - Memory aid - Clinical What the labels mean - Safety Contraindications - Key interactions - What is monitored - Administration and safety - Pregnancy and breastfeeding - Nursing care - Study Test yourself - Connections Connections ## Mechanism of action ◎**EGFR and MET receptors (bispecific antibody)**Amivantamab ⓘ The crystal shows the anti-MET arm of amivantamab bound to the extracellular part of human MET; its other arm binds EGFR. **Target in 3D:** EGFR and MET receptors (bispecific antibody). PDB structure 6WVZ (RCSB PDB, public domain). [View the structure at RCSB PDB](https://www.rcsb.org/structure/6WVZ) · Drag to rotate · pinch to zoom Amivantamab is a bispecific antibody: one arm binds EGFR and the other binds MET. It blocks ligand signalling through both receptors and recruits immune cells that attack the tumour (antibody-dependent cytotoxicity). Because it acts outside the cell, it works against EGFR mutations, such as exon 20 insertions, that resist most EGFR kinase inhibitors. - One arm binds EGFR, the other binds MET - Ligand signalling through both receptors is blocked - Immune cells attack the antibody-coated tumour ## Indications - Metastatic non-small cell lung cancer with EGFR mutations: first line with lazertinib or with carboplatin and pemetrexed, after progression on an EGFR inhibitor with carboplatin and pemetrexed, or alone after platinum. [Lung cancer →](https://durgical.com/en/conditions/lung-cancer/) ## Adverse effects ### Common - Acne-like rash, dry skin, itching - Nail fold inflammation (paronychia) - Swelling of hands and feet, mouth sores - Muscle and joint pain, fatigue - Nausea, constipation ### Serious (rare, important) - Infusion-related reactions, mostly with the first dose - Interstitial lung disease or pneumonitis - Severe skin reactions - Eye problems (pain, redness, blurred vision, light sensitivity) - Venous thromboembolism when combined with lazertinib ## Contraindications - Severe hypersensitivity to amivantamab ## Key interactions **Lazertinib (given together)** The combination raises the risk of serious blood clots in the legs and lungs. **Carboplatin and pemetrexed (given together)** Adds chemotherapy toxicity, such as low blood counts. ## What is monitored - Vital signs and symptoms during and after every infusion, especially the first - Skin and nails at each visit - New cough or breathlessness - Eye symptoms; signs of clots when used with lazertinib ## Administration and safety - Intravenous infusion by trained staff, with premedication as ordered. - Close watching for flushing, breathlessness, chills or nausea; infusion slowed or stopped if they occur. - Sun protection, alcohol-free moisturisers and skin care measures are started to prevent rash. ## Pregnancy and breastfeeding Avoid in pregnancy. It may harm the fetus: a pregnancy test is done first, contraception is used during and for months after treatment, and breastfeeding is stopped. ## Nursing care - Give premedication as ordered and stay with the patient during the first infusion. - Teach skin care: sun protection, moisturiser and early reporting of rash or nail changes. - Teach to report new cough, breathlessness or chest pain, and leg swelling or pain. - Teach to stop contact lenses and report eye pain, redness or blurred vision. ## Pharmacokinetics **Absorption** Intravenous infusion in a medical facility, given slowly with close watching. ## Memory aid «Two keys, two locks»: one arm locks EGFR, the other MET, so the tumour loses both escape routes. ## Test yourself Think of the answer, then tap the question to see it. ## Which two receptors does amivantamab bind? EGFR and MET. ## Which EGFR mutation type is a classic reason to use amivantamab? Exon 20 insertions, which respond poorly to most EGFR kinase inhibitors. ## What is the most frequent acute problem with the first infusion? Infusion-related reactions. [Add to my cards (3)](https://durgical.app/estudiar/?add=/en/pharmacology/amivantamab/) [More Pharmacology questions →](https://durgical.com/en/practice/?f=pharmacology) ## What the labels mean **High alert** An error with this medicine can cause serious harm: double checks and protocols are used. **Pregnancy: avoid** Avoid in pregnancy. It may harm the fetus: a pregnancy test is done first, contraception is used during and for months after treatment, and breastfeeding is stopped. ## Connections ## Related drugs 2 - [Osimertinib](https://durgical.com/en/pharmacology/osimertinib/) - [Cetuximab](https://durgical.com/en/pharmacology/cetuximab/) ## Related conditions 1 - [Lung cancer](https://durgical.com/en/conditions/lung-cancer/) [← Back to the class: Antineoplastic monoclonal antibodies](https://durgical.com/en/pharmacology/classes/antineoplastic-monoclonal-antibodies/) Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given. Sources: [Amivantamab-vmjw Injection: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a621034.html) (MedlinePlus (U.S. National Library of Medicine), 2026); [Amivantamab-vmjw - NCI](https://www.cancer.gov/about-cancer/treatment/drugs/amivantamab-vmjw) (National Cancer Institute, 2024); [RCSB PDB - 6WVZ: Crystal structure of anti-MET Fab arm of amivantamab in complex with human MET](https://www.rcsb.org/structure/6WVZ) (RCSB Protein Data Bank, 2026); [ATCDDD - ATC/DDD Index](https://atcddd.fhi.no/atc_ddd_index/?code=L01FX18) (WHO Collaborating Centre for Drug Statistics Methodology, 2026). ## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake Representative model, for educational purposes only. --- Source: https://durgical.com/en/pharmacology/amivantamab/ License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pharmacology/amivantamab/